Skip to main content
An official website of the United States government
Email

The Brain Metastasis & Glioblastoma Interest Group

The Brain Metastases & Glioblastoma (BM-GBM) Interest Group collectively engages in a multidisciplinary dialog to exchange ideas, raise awareness of data and resources, and stimulate translational research toward the development of clinical trials that incorporate radiation sciences for cancer patients with brain metastases and glioblastoma mulitforme (GBM). The BM-GBM Interest Group serves as a networking conduit for interaction with the National Clinical Trials Network (NCTN), Brain Tumor Committees, key investigators at a global level, as well as relevant industry partners. Operationally, the two subgroups of the BM-GBM Interest Group serves the broader community through publication of white papers and editorials.

Goals

  1. To serve as a common platform and forum for the discussion of various pre-clinical translational ideas that have a high likelihood of being developed into clinical trial concepts. This includes evaluation of conventional phase I-II endpoints, but also includes development of novel endpoints, biomarker incorporation, compartmental disease control, novel imaging, patient reported outcomes (including quality of life), and neurocognitive function.
  2. To assist the NCI disease-specific and other Interest Groups specifically in terms of evaluating concepts for brain metastases and GBM.

BM-GBM Interest Group Chairpersons

Brain Metastasis Group

Michelle Kim, M.D., University of Michigan: michekm@med.umich.edu

Minesh Mehta, M.D., FASTRO Miami Cancer Institute: mineshm@baptishealth.net

GBM Subgroup

Rupesh Kotecha, M.D., Miami Cancer Institute: rupeshk@baptisthealth.net

Evanthia Galanis, M.D., Mayo Clinic Rochester galanis.evanthia@mayo.edu

Minesh Mehta, M.D., FASTRO Miami Cancer Institute: mineshm@baptisthealth.net

Teleconference Schedule

The BM-GBM group meets through WebEx on the last Monday of each month at 5:00 p.m. ET, with alternating topics relating to brain metastasis and GBM. Group membership numbers approximately 65.

Activities and Accomplishments

Clinical Trials

  1. Testing the safety of M6620 (VX-970) when given with standard whole brain radiation therapy for the treatment of Brain Metastases from Non-Small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors (clinicaltrials.gov identifiers: NCT02589522)
  2. Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients with Brain Metastases.  (clinicaltrials.gov identifier: NCT02993146)
  3. T-DM1 Alone versus T-DM1 and Metronomic Temozolomide in secondary prevention of HERS2 - positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery. (clinicaltrials.gov identifier: NCT03190967)
  4. Nivolumab, BMS-986205, and Radiation Therapy with or without Temozolomide in Treating Patients with Newly-diagnosed Glioblastoma. (clinicaltrials.gov identifier: NCT04047706)
  5. Testing the use of the Immunotherapy Drugs Ipilimumab and Nivolumab plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy), for Newly-diagnosed MGMT Unmethylated Glioblastoma. (clinicaltrials.gov identifier: NCT04396860)

Publications

  1. R.S. Bindra, E. Galanis, M.P. Mehta, State of the Art:  The Evolving Role of RT in Combined Modality Therapy for GBM, J. Neurooncol, 134 (2017) 477-478 DOI: 10.1007/s 11060-017-2596-4
  2. C.A. Kunos, E. Galanis, J. Buchsbaum, Q. Shi. et/al, Radiation-agent Combinations for Glioblastoma Challenges in Drug Development and Future Considerations. J. Neurooncol, 134 (2017) 551-557, DOI: 10.1007/s11060-017-2458-0

Workshops

  1. M.M. Kim, M.P. Mehta, D.K. Samrt, et.al., National Cancer Institute collaborative workshop on Shaping the Landscape of Brain Metastases Research: Challenges and Recommended Priorities, Lancet Oncol 2023, 24:344-54, DOI: 10.1016/S1470-2045(23)00297-8
  2. NCI Brain Metastases follow-up workshop, October 8, 2024, NCI Shady Grove Campus, Rockville, Maryland

Interested in becoming a member of the BM-GBM Interest Group?

Please contact the Interest Group Coordinator:

J. Manuel Perez, Ph.D.
Radiation Research Program,
Division of Cancer Research and Diagnosis
National Cancer Institute
jmanuel.perez@nih.gov

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “The Brain Metastasis & Glioblastoma Interest Group was originally published by the National Cancer Institute.”

Email